目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information/Data Analysis
1.5. Market Formulation & Visualization
1.6. Data Validation & Publishing
1.7. Model Details
1.7.1. Commodity flow analysis
1.7.2. Global Market: CAGR Calculation
1.8. List of Secondary Sources

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Hemato oncology testing Market Variable Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market
3.1.2. Ancillary Market
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of lymphoma & myeloma
3.2.1.2. Growing demand for personalized therapy
3.2.1.3. Availability of advanced molecular techniques for hemato oncology diagnostics
3.2.1.4. Increasing drug-diagnostics co-development
3.2.2. Market Restraint Analysis
3.2.2.1. Favorable reimbursement scenario
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. Hemato oncology testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitution
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal Landscape
3.3.2.2. Economic and Social Landscape
3.3.2.3. Technological landscape
3.3.2.4. Environmental Landscape
3.3.3. Regulatory Framework

Chapter 4. Hemato oncology testing Market: Cancer Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Hemato oncology testing Market Cancer Movement Analysis
4.3. Hemato oncology testing Market Size & Trend Analysis, By Cancer, 2018 - 2030 (USD Million)
4.4. Leukemia
4.4.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2. Acute Myeloid Leukemia (AML)
4.4.2.1. Acute Myeloid Leukemia (AML) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.2. Acute Lymphocytic Leukemia (ALL)
4.4.2.2.1. Acute Lymphocytic Leukemia (ALL) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.3. Chronic Lymphocytic Leukemia
4.4.2.3.1. Chronic Lymphocytic Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.4. Chronic Myeloid Leukemia
4.4.2.4.1. Chronic Myeloid Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Lymphoma
4.5.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.1. Non-Hodgkin Lymphoma
4.5.1.1.1. Non-Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.2. Hodgkin Lymphoma
4.5.1.2.1. Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Myeloproliferative Neoplasms
4.6.1. Myeloproliferative Neoplasms Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.2 Polycythemia vera (PV)
4.6.2.1 Polycythemia vera (PV) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.3 Essential thrombocythemia (ET)
4.6.3.1 Essential thrombocythemia (ET) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.4 Myelofibrosis (MF)
4.6.4.1 Myelofibrosis (MF) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Other Cancers
4.7.1. Other Cancers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hemato oncology testing Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Hemato oncology testing Market Product Movement Analysis
5.3. Hemato oncology testing Market Size & Trend Analysis, By Product 2018 - 2030 (USD Million)
5.3.1. Assay Kits and Reagents
5.3.1.1. Assay Kits and Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.1.2. Services
5.3.1.2.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hemato oncology testing Market: Technology Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Hemato oncology testing Market Technology Movement Analysis
6.3. Hemato oncology testing Market Size & Trend Analysis, By Technology, 2018 - 2030 (USD Million)
6.3.1. PCR
6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.1.2. Real-time qPCR
6.3.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.1.3. Digital PCR
6.3.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.1.3.2.
6.3.2. IHC
6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. NGS
6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.4. Cytogenetics
6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.5. Other Technologies
6.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Hemato oncology testing Market: End Use Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Hemato oncology testing Market End Use Movement Analysis
7.3. Hemato oncology testing Market Size & Trend Analysis, By End Use 2018 - 2030 (USD Million)
7.3.1. Hospitals
7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Academic & Research Institutes
7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Others
7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Participants Overview
8.3. Financial Performance
8.4. Product Benchmarking
8.5. Market Position Analysis, 2024 (Heat Map Analysis)
8.6. Strategy Mapping
8.6.1. Mergers and Acquisitions
8.6.2. Launch
8.6.3. Partnerships & Collaborations
8.6.4. Expansion
8.6.5. Others
8.7. Company Profiles
8.7.1. F. Hoffmann-La Roche Ltd
8.7.1.1. Participant’s overview
8.7.1.2. Financial performance
8.7.1.3. Product Benchmarking
8.7.1.4. Strategic initiatives
8.7.2. Abbott
8.7.2.1. Participant’s overview
8.7.2.2. Financial performance
8.7.2.3. Product Benchmarking
8.7.2.4. Strategic initiatives
8.7.3. EntroGen, Inc.
8.7.3.1. Participant’s overview
8.7.3.2. Financial performance
8.7.3.3. Product Benchmarking
8.7.3.4. Strategic initiatives
8.7.4. Qiagen N.V.
8.7.4.1. Participant’s overview
8.7.4.2. Financial performance
8.7.4.3. Product Benchmarking
8.7.4.4. Strategic initiatives
8.7.5. Cepheid (Danaher Corporation)
8.7.5.1. Participant’s overview
8.7.5.2. Financial performance
8.7.5.3. Product Benchmarking
8.7.5.4. Strategic initiatives
8.7.6. Thermo Fisher Scientific, Inc.
8.7.6.1. Participant’s overview
8.7.6.2. Financial performance
8.7.6.3. Product Benchmarking
8.7.6.4. Strategic initiatives
8.7.7. Bio-Rad Laboratories, Inc.
8.7.7.1. Participant’s overview
8.7.7.2. Financial performance
8.7.7.3. Product Benchmarking
8.7.7.4. Strategic initiatives
8.7.8. Illumina, Inc.
8.7.8.1. Participant’s overview
8.7.8.2. Financial performance
8.7.8.3. Product Benchmarking
8.7.8.4. Strategic initiatives
8.7.9. Amoy Diagnostics Co., Ltd.
8.7.9.1. Participant’s overview
8.7.9.2. Financial performance
8.7.9.3. Product Benchmarking
8.7.9.4. Strategic initiatives
8.7.10. ASURAGEN, INC
8.7.10.1. Participant’s overview
8.7.10.2. Financial performance
8.7.10.3. Product Benchmarking
8.7.10.4. Strategic initiatives
8.7.11. ArcherDX, Inc. (IDT)
8.7.11.1. Participant’s overview
8.7.11.2. Financial performance
8.7.11.3. Product Benchmarking
8.7.11.4. Strategic initiatives
8.8. List of Other Market Players

Chapter 9. Key Takeaways

List of Tables
Tables 1 List of Secondary Sources
Tables 2 List of Abbreviations
Tables 3 Hemato oncology testing market, by Cancer, 2018 - 2030 (USD Million)
Tables 4 Hemato oncology testing market, by Product, 2018 - 2030 (USD Million)
Tables 5 Hemato oncology testing market, by Technology, 2018 - 2030 (USD Million)
Tables 6 Hemato oncology testing market, by End Use, 2018 - 2030 (USD Million)
Tables 7 Company Overview
Tables 8 Service Benchmarking
Tables 9 Financial Performance
Tables 10 Strategic Initiatives

List of Figures
Fig. 1 Hemato oncology testing market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Data Analysis Models
Fig. 6 Market Formulation And Validation
Fig. 7 Data Validating & Publishing
Fig. 8 General methodology for a commodity flow analysis of Hemato oncology testing market
Fig. 9 Commodity flow analysis
Fig. 10 Parent market analysis
Fig. 11 Market snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Parent market value, 2024 (USD Billion)
Fig. 16 Ancillary market outlook, 2024
Fig. 17 Hemato oncology testing market Dynamics
Fig. 18 Hemato oncology testing market: PORTER’s analysis
Fig. 19 Hemato oncology testing market: PESTEL analysis
Fig. 20 Hemato oncology testing market by Cancer: Key Takeaways
Fig. 21 Hemato oncology testing market by Cancer, 2024 & 2030
Fig. 22 Leukemia market, 2018 - 2030 (USD Million)
Fig. 23 Acute Myeloid Leukemia (AML) market, 2018 - 2030 (USD Million)
Fig. 24 Acute Lymphocytic Leukemia (ALL) market, 2018 - 2030 (USD Million)
Fig. 25 Chronic Lymphocytic Leukemia market, 2018 - 2030 (USD Million)
Fig. 26 Chronic Myeloid Leukemia market, 2018 - 2030 (USD Million)
Fig. 27 Lymphoma market, 2018 - 2030 (USD Million)
Fig. 28 Non-Hodgkin Lymphoma market, 2018 - 2030 (USD Million)
Fig. 29 Hodgkin Lymphoma market, 2018 - 2030 (USD Million)
Fig. 30 Myeloproliferative Neoplasms market, 2018 - 2030 (USD Million)
Fig. 31 Polycythemia vera (PV) market, 2018 - 2030 (USD Million)
Fig. 32 Essential thrombocythemia (ET) market, 2018 - 2030 (USD Million)
Fig. 33 Myelofibrosis (MF) market, 2018 - 2030 (USD Million)
Fig. 34 Other Cancers market, 2018 - 2030 (USD Million)
Fig. 35 Hemato oncology testing market by Product: Key Takeaways
Fig. 36 Hemato oncology testing market by Product, Market Share, 2024 & 2030
Fig. 37 Assay Kits and Reagents market, 2018 - 2030 (USD Million)
Fig. 38 Hemato oncology testing market by Technology: Key Takeaways
Fig. 39 Hemato oncology testing market by Technology, Market Share, 2024 & 2030
Fig. 40 PCR market, 2018 - 2030 (USD Million)
Fig. 41 Real-time qPCR market, 2018 - 2030 (USD Million)
Fig. 42 Digital PCR market, 2018 - 2030 (USD Million)
Fig. 43 IHC market, 2018 - 2030 (USD Million)
Fig. 44 NGS market, 2018 - 2030 (USD Million)
Fig. 45 Cytogenetics market, 2018 - 2030 (USD Million)
Fig. 46 Other technologies market, 2018 - 2030 (USD Million)
Fig. 47 Hemato oncology testing market by End Use Outlook: Key Takeaways
Fig. 48 Hemato oncology testing market by End Use Outlook, Market Share, 2024 & 2030
Fig. 49 Hospitals, 2018 - 2030 (USD Million)
Fig. 50 Academic & Research Institutes market, 2018 - 2030 (USD Million)
Fig. 51 Others market, 2018 - 2030 (USD Million)
Fig. 52 Market Participant Categorization
Fig. 53 Heat map analysis
Fig. 54 Strategic Framework